Best of the Week
Most Popular
1.Canada Real Estate Bubble - Harry_Dent
2.UK House Prices ‘On Brink’ Of Massive 40% Collapse - GoldCore
3.Best Cash ISA for Soaring Inflation, Kent Reliance Illustrates the Great ISA Rip Off - Nadeem_Walayat
4.Understanding true money, Pound Sterling must make another historic low, Euro and Gold outlook! - Marc_Horn
5.5 Maps That Explain The Modern Middle East - GEORGE FRIEDMAN
6.Gold Back With A Vengeance As Bitcoin Bubble Bursts - OilPrice_Com
7.Gold Summer Doldrums - Zeal_LLC
8.Crude Oil Trade & Nasdaq QQQ Update - Plunger
9.Gold And Silver – Why No Rally? Lies, Lies, And More Lies - Michael_Noonan
10.UK Election 2017 Disaster, Fake BrExit Chaos, Forecasting Lessons for Next Time - Nadeem_Walayat
Last 7 days
Students, It’s Time to Prepare Your Finances for the Years Ahead - 25th Jul 17
Stock Market and Gold Stocks Trend Forecast Update - 25th Jul 17
Saving Illinois: Getting More Bang for Its Bucks - 24th Jul 17
3 Stocks Sectors That Will Win in The Fed’s Great Balance-Sheet Unwind - 24th Jul 17
Activist Investors Are Taking Over Wall Street, Procter and Gamble Might Never Remain the Same - 24th Jul 17
Stock Market Still on Track - 24th Jul 17
Last Chance For US Dollar To Rally - 24th Jul 17
UK House Prices Momentum Crash Warns of 2017 Bear Market - Video - 22nd Jul 17
Crude Oil, Gold, ETFs & more: Pro-grade Market Forecasts - 22nd Jul 17
Warning: The Fed Is Preparing to Crash the Financial System Again - 21st Jul 17
Gold / Silver Shorts Extreme - 21st Jul 17
GBP/USD Bearish Factors - 21st Jul 17
Gold Hedges Against Currency Devaluation and Cost Of Fuel, Food, Beer and Housing - 21st Jul 17
Is It Worth Investing in Palladium? - 21st Jul 17
UK House Prices Momentum Crash Threatens Mini Bear Market 2017 - 21st Jul 17
The Fed May Show Trump No Love - 20th Jul 17
The 3 Best Asset Classes To Brace Your Portfolio For The Next Financial Crisis - 20th Jul 17
Gold Stocks and Bonds - Preparing for THE Bottom - 20th Jul 17
Millennials Can Punt On Bitcoin, Own Safe Haven Gold For Long Term - 20th Jul 17
Trump Has Found A Loophole To Rewrite Trade Agreements Without Anyone’s Permission - 20th Jul 17
Basic Materials and Commodities Analysis and Trend Forecasts - 20th Jul 17
Bitcoin PullBack Is Over (For Now): Cryptocurrencies Gain Nearly A 50% In Last 48 Hours - 19th Jul 17
AAPL's 6% June slide - When Prices Are Falling, TWO Numbers Matter Most - 19th Jul 17
Discover Why A Major American Revolution Is Brewing - 19th Jul 17
iGaming – Stock Prices - 19th Jul 17
The Socionomic Theory of Finance By Robert Prechter - Book Review - 18th Jul 17
Ethereum Versus Bitcoin – Which Cryptocurrency Will Win The War? - 18th Jul 17
Accepting a Society of Government Tyranny - 18th Jul 17
Gold Cheaper Than Buying Greek Villas in 2012 - 18th Jul 17
Why & How to Hedge the Growing Risks of Holding Stocks - 18th Jul 17
Relocation: Everything You Need to do for a Smooth Transition Abroad - 17th Jul 17
A Former Lehman Brothers Trader: It’s Time To Buy Brick And Mortar Retailers - 17th Jul 17
Bank Of England Warns “Bigger Systemic Risk” Now Than 2008 - 17th Jul 17
Bitcoin Price “Deja Vu” Corrective Sequence - 17th Jul 17
Charting New Low in Speculation in Gold and Silver Markets - 17th Jul 17
Bitcoin Crash - Is This The End of Cryptocurrencies? - 17th Jul 17
The Fed's Inflation Nightmare Scenario - 17th Jul 17
Billionaire Investors Backing A Marijuana Boom In 2017 - 17th Jul 17
Perfect Storm - This Fourth Turning has Over a Decade of Continuous Storms to Come - 17th Jul 17
Gold and Silver Biggest Opportunity Since Late 2015, Last Chance at These Prices - 17th Jul 17
Stock Market More to Go - 17th Jul 17
Emerging Markets & Basic Materials Stocks Breaking Out Together - 16th Jul 17
Stock Market SPX Uptrending Again After Microscopic Correction - 15th Jul 17

Market Oracle FREE Newsletter

Crude Oil, Gold, ETFs & more: Pro-grade Market Forecasts

After The Crash - Digital And Regenerative Medicine, Live for Ever!

Companies / BioTech Apr 23, 2017 - 04:01 AM GMT

By: John_Rubino

Companies

For most people, the doctor visit hasn’t changed in decades. Same physical waiting rooms, same paper forms to fill out, same slow, expensive tests and marginally-effective, maximally-invasive treatments. But that’s about to change, as a wave of new technologies drag medicine into the 21st century. Among the most interesting:


Digitized research. Instead of laboriously searching for medicines in the natural world, today’s scientists use algorithms to design thousands of chemicals and “labs on a chip” to test them quickly and accurately. The result: processes that used to take years now take months, weeks, or days, resulting in a tidal wave of powerful new drugs in various stages of development.

Cheap, fast tests. Many of today’s medical tests require the culturing of cells in a lab to get enough genetic material to analyze. For example, testing for sepsis (a common, extremely dangerous infection) might take three days and cost $2,000. But several start-ups are introducing advanced molecular diagnostic tools that can test for sepsis in few hours for less than $100. Lots of other tests are being simplified in this way.

Synthetic biology. The emerging ability to mix and match genetic material — or build it from scratch — to create new life forms is allowing researchers to, for instance, harness specially-designed bacteria to mass produce next-generation antibiotics, vaccines and cancer drugs.

Genomics for the masses. Sequencing the first human genome required $3 billion and 13 years. 15 years later, the $1,000, 24-hour genome is in sight. The possibilities opened up by widely-available genomics include the ability to determine which cancer drug will work on which cancer, something today’s oncologists can only guess at.

Stem cells. Undifferentiated cells that can become anything from neurons to entire new organs were discovered more than three decades ago. But only in the past couple of years has it become possible to make them follow instructions. Scientists are now growing cartilage to repair damaged joints that previously required surgery, while others are creating entire new organs for transplantation.

Trillion-dollar market
Healthcare is one of the two or three biggest global markets, encompassing everything from large pharmaceutical companies and medical device makers to hundreds of start-ups bringing potentially disruptive products to market. So even relatively small niches are potential billion-dollar businesses.

That means a couple of things. First, lots of action. Big companies will be buying out emerging players and new breakthroughs will be announced by labs around the world on a daily basis. So nothing is certain and everything is in flux, which pretty much defines the intellectual challenge of a hot industry. Second, the breakthrough technologies all sound spectacular but, based on the history of previous paradigm shifts, only a tiny minority will ever make it to market. So skepticism is more important here than in normal sectors.

So the best way to approach this kind of industry is to 1) never believe anything you hear until real proof accompanies the wild assertions, 2) diversify across sub-sectors to moderate their volatility, and 3) identify and seek the help of experts. Here’s a (very partial) list of biotech related news feeds and newsletters:

FierceBiotech

Prohost Biotechnology

‎Prudent Biotech Newsletter

BioInvest

BioPortfolio

Biotech Newsletters – Stockfocus.com

Currin Biotech Investment Newsletter

Biotechnology News — ScienceDaily

And a few representative articles:

Next-Generation Genomics, Precision Medicine to Top $100B

Luminex to Acquire Nanosphere for 69% premium to previous day’s close

A Pure Regenerative Medicine Play

Silicon Valley elites look to live forever

*Most of these stocks will tank in the coming equities bear market. At the bottom — after the crash — potential ten-baggers will be common. So get up to speed on them now. For the previous article in this series, see After The Crash, Part 1: Solar Stocks

By John Rubino

dollarcollapse.com

Copyright 2017 © John Rubino - All Rights Reserved

Disclaimer: The above is a matter of opinion provided for general information purposes only and is not intended as investment advice. Information and analysis above are derived from sources and utilising methods believed to be reliable, but we cannot accept responsibility for any losses you may incur as a result of this analysis. Individuals should consult with their personal financial advisors.


© 2005-2017 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in

Catching a Falling Financial Knife